Program
bictegravir
Also written as “B/F/TAF”, “Bictegravir” and “BIC/LEN FDC”.
Its studies are mostly in Coinfection · Kidney Failure, Chronic · Mesothelioma, Malignant, led by 3 companies.
Drug pageBictegravir: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 238 open or running | phase 4since Oct 23, 2023 | Oct 23, 2014 | Aug 2027phase 2 · NCT07645287 |
| AGC Biologicsits history only | 10 open or running | phase 3since Mar 17, 2010 | Mar 17, 2010 | none ahead |
| Merckits history only | 10 open or running | phase 1since Apr 8, 2026 | Apr 8, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 12 earlier studies, Mar 17, 2010 to May 24, 2018.
- Jun 9, 2015Named bictegravirINNProposed as its International Nonproprietary Name in WHO's List 113
- Aug 13, 2018Phase 3 study in HIV-1 InfectionGilead Sciences · NCT03631732 · 496 enrolled · United States
- May 21, 2019Phase 1 study in HIV-1-infectionGilead Sciences · NCT03960645 · 62 enrolled · United States, Dominican Republic, Thailand
- Oct 28, 2019Phase 2 study in HIV-1-infectionGilead Sciences · NCT04143594 · 183 enrolled · United States, Dominican Republic, Puerto Rico
- Aug 5, 2022Phase 3 study in HIV-1-infectionGilead Sciences · NCT05502341 · 689 enrolled · United States, Argentina, Australia and more
- Oct 23, 2023Phase 4 study in HIV-1-infectionGilead Sciences · NCT06104306 · 33 enrolled · United States, Canada, France
- Mar 20, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06333808 · 577 enrolled · United States, Argentina, Australia and more
- Jul 29, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06532656 · 75 enrolled · United States, Argentina, Italy and more
- Oct 4, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06630286 · 609 enrolled · United States, Argentina, Australia and more
- Jun 27, 2025Phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451 · 16 enrolled · United States, South Africa
- Apr 8, 2026Merck’s first study: phase 1 study in HealthyNew to MerckMerck · NCT07532304 · 16 enrolled · United States
- Jun 8, 2026Phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287 · 175 planned · United States, Australia, Canada and more
- Jul 13, 2026Phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727 · 700 planned · United States, Canada, Germany and more
- Sep 29, 2026Primary completion moved from 2026-11 to 2030-07Date moved laterphase 3 · +44 months · NCT06532656
- Oct 26, 2026Phase 4 study in HIV-1 InfectionGilead Sciences · NCT07908446 · 400 planned
Ahead
- Aug 2027Primary completion: phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287
- Mar 2028Primary completion: phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451
- Jul 2028Primary completion: phase 4 study in HIV-1 InfectionGilead Sciences · NCT07908446
- Jul 2030Primary completion: phase 3 study in HIV-1-infectionGilead Sciences · NCT06532656
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 integrase inhibitor; Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07908446HIV-1 Infection | 4 | Not yet recruiting | Gilead Sciences | Jul 2028 | 400 |
| NCT07708727HIV-1-infection · United States, Canada, Germany and more | 3 | Recruiting | Gilead Sciences | Oct 2030 | 700 |
| NCT07645287HIV-1-infection · United States, Australia, Canada and more | 2 | Recruiting | Gilead Sciences | Aug 2027 | 175 |
| NCT07532304Healthy · United States | 1 | Completed | Merck | Jul 23, 2026 | 16 |
| NCT07055451HIV-1-infection · United States, South Africa | 1 | Active, not recruiting | Gilead Sciences | Mar 2028 | 16 |
| NCT06630286HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Apr 17, 2026 | 609 |
| NCT06532656HIV-1-infection · United States, Argentina, Italy and more | 3 | Active, not recruiting | Gilead Sciences | Jul 2030 | 75 |
| NCT06333808HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Oct 27, 2025 | 577 |
| NCT06104306HIV-1-infection · United States, Canada, France | 4 | Completed | Gilead Sciences | Jan 29, 2025 | 33 |
| NCT05502341HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Sep 29, 2025 | 689 |
| NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico | 2 | Completed | Gilead Sciences | Oct 5, 2021 | 183 |
| NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand | 1 | Completed | Gilead Sciences | Jul 21, 2022 | 62 |
| NCT03631732HIV-1 Infection · United States | 3 | Completed | Gilead Sciences | Aug 12, 2019 | 496 |
| NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more | 3 | Completed | Gilead Sciences | Feb 25, 2022 | 244 |
| NCT03405935HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Gilead Sciences | Nov 20, 2018 | 86 |
| NCT03110380HIV-1-infection · United States, Austria, Canada and more | 3 | Completed | Gilead Sciences | Dec 4, 2018 | 567 |
| NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more | 3 | Completed | Gilead Sciences | Oct 9, 2017 | 472 |
| NCT02607956HIV-1 Infection · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | May 12, 2017 | 657 |
| NCT02607930HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | May 9, 2017 | 631 |
| NCT02603120HIV-1 Infection · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | May 9, 2017 | 567 |
| NCT02600819Kidney Failure, Chronic · United States, Austria, France and more | 3 | Completed | Gilead Sciences | Sep 29, 2017 | 55 |
| NCT02397694HIV-1 Infection · United States | 2 | Completed | Gilead Sciences | Nov 30, 2015 | 98 |
| NCT02400307HIV · United States, New Zealand | 1 | Completed | Gilead Sciences | Jul 6, 2015 | 19 |
| NCT02275065HIV-1 Infection · United States | 1 | Completed | Gilead Sciences | Jan 23, 2015 | 23 |
| NCT01098266Mesothelioma, Malignant · United States, Belgium, Canada and more | 3 | Completed | AGC Biologics | Apr 29, 2014 | 400 |
How it is read
Names in the registry
- “B/F/TAF”, 16 entries
- “Bictegravir”, 3 entries
- “BIC/LEN FDC”, 2 entries
- “Bictegravir/Lenacapavir (BIC/LEN) FDC”, 2 entries
- “Bictegravir/Lenacapavir”, 1 entry
Conditions, from the studies’ own filings
- Coinfection, 1 study
- Kidney Failure, Chronic, 1 study
- Mesothelioma, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.